Prognostic implications of dual tracer PET/CT: PSMA ligand and [(18)F]FDG PET/CT in patients undergoing [(177)Lu]PSMA radioligand therapy

BACKGROUND: Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) with (177)Lu-labeled PSMA ligands has achieved remarkable results in advanced disease stages of metastatic castration-resistant prostate cancer (mCRPC). However, not all patients benefit from this therapy. Diffe...

Descripción completa

Detalles Bibliográficos
Autores principales: Michalski, Kerstin, Ruf, Juri, Goetz, Christian, Seitz, Anna Katharina, Buck, Andreas K., Lapa, Constantin, Hartrampf, Philipp E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113196/
https://www.ncbi.nlm.nih.gov/pubmed/33336265
http://dx.doi.org/10.1007/s00259-020-05160-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113196/
https://www.ncbi.nlm.nih.gov/pubmed/33336265
http://dx.doi.org/10.1007/s00259-020-05160-8

Ejemplares similares